Hematology Advisor Institute Spotlight Course

The Distinctive Role of BCMA-Targeting Therapies in Relapsed/Refractory Multiple Myeloma

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.50 CME CE: Reviews data on how BCMA-targeting therapies help improve survival in patients with relapsed/refractory multiple myeloma. Exp 10/31/23

Maintenance Therapy and the Patient Voice in AML | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s)

1.25 CME CE: Complex case-based scenarios managing patients with AML through induction, consolidation, transplant, and maintenance therapies. Exp 8/11/23

Beta Thalassemia Advances : Reducing Transfusion Burden | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: This interactive e-journal article covers pathophysiology, diagnostic criteria, clinical trial data, and transition preparedness strategies. Exp 3/11/2023

Optimal Therapy for Vulnerable Follicular Lymphoma Patients | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), ABIM MOC Points, CE for Pharmacists, AAPA Category I CME Credit

0.50 CME CE: This final installment in a 3-part series assesses the needs of older patients with FL when creating treatment plans. Exp. 3/9/2023

Management of Follicular Lymphoma | myCME

ANCC Contact Hour(s)

1.50 CE: Focuses on oncology nurse role in FL and discusses advances treatment, including updates to guidelines and two novel agents. Exp 4/29/23

Novel Targets for Higher-risk Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Examine clinical data supporting the importance of differential diagnosis, risk stratification, and emerging therapies. Exp 2/24/23

Improving Long-Term Outcomes in AML: Maintenance Therapy | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, ANCC Contact Hour(s)

1.00 CME CE: An interactive infographic activity on AML maintenance therapy. Exp 7/15/23

Ring Sideroblast Quantification in Myelodysplastic Syndromes | myCME

AMA PRA Category 1 Credit(s)^TM

1.50 CME: Symposium on pathology of MDS-RS includes a cross-disciplinary interview enhanced by infographics and pathologist pocket guide. Exp 4/28/2023

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

1.00 CME CE: A lively expert discussion and real-world clinical case on PNH. Exp 6/30/23

Immune Related Adverse Events in Checkpoint Inhibitor Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), AAPA Category I CME Credit

1.00 CME CE: This module will immerse clinicians in how to safely practice applying new clinical concepts in managing imAEs in patients receiving ICI treatment. Exp. 4/19/23

Optimizing Outcomes in Low-Risk MDS | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: In-depth discussion for healthcare practitioners who manage patients with low-risk MDS so they can to better recognize the types of MDS. Exp 4/29/23

Targeted Therapy for NSCLC: New Frontiers | myCME

ANCC Contact Hour(s), IPCE Credit(s)

1.00 CE: Dr. Marianne Davies discusses current molecular testing guidelines; molecular profile-based, targeted-treatment strategies; and more. Exp 4/29/23

CLL: Oncology Nurse Strategies in Therapy Management | myCME

ANCC Contact Hour(s)

1.00 CE: Emerging advances in CLL treatment with novel agents and the latest trial data for monotherapy and combination therapy strategies. Exp 12/2/22